Korro Bio (NASDAQ:KRRO) CEO Ram Aiyar Sells 15,152 Shares of Stock

Korro Bio, Inc. (NASDAQ:KRRO) CEO Ram Aiyar sold 15,152 shares of the business’s stock in a transaction dated Friday, May 29th. The shares were sold at an average price of $12.98, for a total value of $196,672.96. Following the completion of the sale, the chief executive officer directly owned 74,848 shares of the company’s stock, valued at $971,527.04. The trade was a 16.84% decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. The sale was made to cover tax withholding obligations related to the vesting of equity awards.

Korro Bio Price Performance

Shares of Korro Bio stock opened at $11.00 on Wednesday. Korro Bio, Inc. has a one year low of $5.20 and a one year high of $55.89. The firm has a market capitalization of $158.62 million, a price-to-earnings ratio of -0.94 and a beta of 3.00. The business has a 50-day simple moving average of $12.37 and a 200 day simple moving average of $10.63.

Korro Bio (NASDAQ:KRRO) last issued its earnings results on Thursday, May 7th. The company reported ($1.69) EPS for the quarter, missing analysts’ consensus estimates of ($1.60) by ($0.09). Korro Bio had a negative net margin of 1,834.48% and a negative return on equity of 117.86%. On average, sell-side analysts expect that Korro Bio, Inc. will post -5.36 EPS for the current year.

Institutional Trading of Korro Bio

Hedge funds and other institutional investors have recently added to or reduced their stakes in the stock. JPMorgan Chase & Co. boosted its stake in shares of Korro Bio by 6,185.5% in the 3rd quarter. JPMorgan Chase & Co. now owns 199,249 shares of the company’s stock worth $9,542,000 after buying an additional 196,079 shares during the last quarter. Algert Global LLC purchased a new position in shares of Korro Bio in the 3rd quarter worth approximately $340,000. Quadrature Capital Ltd purchased a new position in shares of Korro Bio in the 4th quarter worth approximately $217,000. Engineers Gate Manager LP purchased a new position in shares of Korro Bio in the 4th quarter worth approximately $215,000. Finally, Deutsche Bank AG boosted its stake in shares of Korro Bio by 241.9% in the 4th quarter. Deutsche Bank AG now owns 12,758 shares of the company’s stock worth $102,000 after buying an additional 9,027 shares during the last quarter. 13.18% of the stock is owned by institutional investors.

Analyst Upgrades and Downgrades

A number of analysts recently commented on KRRO shares. Cantor Fitzgerald boosted their target price on Korro Bio from $21.00 to $22.00 and gave the company an “overweight” rating in a research report on Friday, March 13th. HC Wainwright decreased their price objective on Korro Bio from $20.00 to $15.00 and set a “buy” rating for the company in a report on Tuesday, May 19th. William Blair raised Korro Bio from a “market perform” rating to an “outperform” rating in a report on Tuesday, February 17th. JonesTrading raised Korro Bio from a “hold” rating to a “strong-buy” rating in a report on Friday, May 8th. Finally, Weiss Ratings reissued a “sell (d-)” rating on shares of Korro Bio in a report on Wednesday, April 8th. Three investment analysts have rated the stock with a Strong Buy rating, six have assigned a Buy rating, two have assigned a Hold rating and one has issued a Sell rating to the stock. According to data from MarketBeat, the company presently has a consensus rating of “Moderate Buy” and an average target price of $16.71.

Korro Bio News Summary

Here are the key news stories impacting Korro Bio this week:

• Negative Sentiment: CEO Ram Aiyar sold 15,152 shares on May 29 at an average price of $12.98, reducing his ownership by 16.84%. The sale was disclosed as being tied to tax withholding on vested equity awards, but insider selling can still weigh on sentiment. SEC filing
• Negative Sentiment: Director Jean Francois Formela sold 2,860 shares on May 28 at $13.95, a transaction made under a pre-arranged 10b5-1 trading plan. While routine, the sale adds to the recent insider-selling overhang. SEC filing
• Neutral Sentiment: Lifesci Capital initiated/updated coverage with a “Strong-Buy” rating and published earnings estimates that are slightly better than the broader consensus for FY2026 through FY2030, which supports the long-term outlook but does not offset near-term losses.
• Negative Sentiment: The company’s most recent quarterly results missed EPS expectations, and Korro Bio continues to post sizable losses, reinforcing concerns about cash burn and profitability.

About Korro Bio

Korro Bio, Inc is a clinical-stage biotechnology company focused on harnessing advanced protein engineering and synthetic biology to develop novel enzyme therapies and live microbial therapeutics. The company’s proprietary platform integrates directed evolution, high-throughput screening and computational design to optimize biological catalysts for a wide range of applications. By combining machine learning with experimental biology, Korro Bio seeks to accelerate the discovery and development of next-generation treatments for rare genetic disorders and complex metabolic diseases.

The company’s pipeline features both engineered enzyme therapeutics and live biotherapeutics.